港股异动 | 和黄医药急升逾 5% 沃瑞沙于中国首次商业销售 获阿斯利康里程碑付款

Zhitong
2021.07.15 05:54
智通财经 APP 获悉，和黄医药 (00013) 发布公告，沃瑞沙 (通用名：赛沃替尼/savolitinib) 于今年 7 月 12 日首次在中国进行商业销售，触发阿斯利康 (AZN.US) 一笔 2500 万美元的里程碑付款。截至发稿，和黄医药涨 4.87%，报 60.25 港元，成交额 3699.57 万港元。
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.